Report Description Table of Contents What Is the Drug Repurposing Market Size and Why Are Existing Medicines Becoming Strategic Development Assets? – (Updated On: 01-Sep-2026) The Global Drug Repurposing Market was valued at USD 4.85 billion in 2025 and is projected to reach USD 8.72 billion by 2032, expanding at a CAGR of 8.7% during 2026–2032, according to Strategic Market Research. This represents a CAGR of 8.7% during 2026–2032. The market is gaining relevance as pharmaceutical developers seek faster and less risky pathways to address unmet medical needs. Repurposing builds on existing clinical, safety, and pharmacological evidence. This can improve development efficiency and reduce uncertainty compared with creating a new molecular entity. The opportunity is significant. Around 3,000 approved drugs exist, while nearly 9,000 diseases still lack an approved therapy. Repurposed candidates achieve an approval success rate of about 30%, versus roughly 10–11% for traditional drug development. Timelines can also decline from 10–17 years to about 3–12 years. Development costs may be reduced to nearly half. The commercial and clinical impact is already visible. Repurposed products account for roughly 30–40% of annual pharmaceutical approvals and applications in some analyses. Between 1985 and 2024, 451 major drugs in the U.S. received approval for new therapeutic uses. Around 15% of orphan drug designations also involve repurposing strategies. These figures support market growth because they demonstrate that repurposing is becoming a practical development model rather than a niche approach. AI, machine learning, network medicine, and knowledge graphs are further improving candidate selection. This helps developers prioritize clinically meaningful opportunities, reduce failed programs, shorten patient access timelines, and improve the economic viability of drug development. SMR Market Scope The USD 4.85 billion market estimate captures commercial value generated specifically by new-use development and commercialization, repurposing technology and evidence platforms, and specialist development services. It excludes revenue attributable solely to a medicine’s original approved indication. Off-label utilization is treated as an adjacent access pathway unless it is linked to repurposing-specific evidence, licensing, development, or commercialization activity. Drug Repurposing Market Key Takeaways: Where Commercial Value Is Concentrated Segment Category Subsegment 2025 Market Share 2025 Market Size CAGR (2026–2032) Market Write-Up Therapeutic Area Oncology 36.5% USD 1.77 Bn 9.5% Oncology leads the market because label modernization, biomarker-defined populations, compendia-supported off-label use, and established clinical-development infrastructure provide multiple routes for converting existing cancer medicines into new therapeutic applications. Neurology 18.5% USD 0.90 Bn 9.2% Neurology represents a significant repurposing opportunity as high attrition in novel CNS drug development encourages evaluation of established compounds across Alzheimer’s disease, neurodegenerative disorders, and rare neurological conditions. Infectious Diseases 16.0% USD 0.78 Bn 8.9% Existing safety data, manufacturing availability, and the ability to prioritize known medicines rapidly make repurposing particularly relevant during infectious-disease outbreaks and emerging public-health threats. Cardiovascular Disorders 10.5% USD 0.51 Bn 7.2% Cardiovascular repurposing is largely driven by lifecycle and indication expansion, where established medicines gain additional clinical roles after outcomes studies demonstrate benefits in adjacent cardiometabolic populations. Autoimmune & Inflammatory Conditions 10.5% USD 0.51 Bn 8.5% Shared cytokine, inflammatory, and immune pathways allow existing immunomodulators and targeted therapies to be evaluated across multiple immune-mediated diseases, particularly where the biological target is already clinically validated. Others 8.0% USD 0.39 Bn 5.9% Rare, neglected, genetic, metabolic, and fibrotic diseases provide selective opportunities where conventional drug discovery economics are difficult but an existing compound has a credible mechanistic or clinical rationale. Drug Type Small Molecules 79.0% USD 3.83 Bn 8.2% Small molecules dominate because extensive human exposure data, established manufacturing, generic availability, oral administration, and formulation flexibility create a large pool of compounds suitable for new-indication development. Biologics 21.0% USD 1.02 Bn 10.6% Biologics hold a smaller share but are growing faster as targeted immune and molecular pathways allow antibodies and other biologic therapies to expand into additional indications while sponsors often retain greater control over manufacturing and clinical data. Technology Platform Computational Modeling & AI-Based Screening 36.0% USD 1.75 Bn 10.3% AI-based platforms lead the technology segment by integrating drug-target relationships, disease biology, literature, omics, and clinical data to rank large numbers of drug-disease combinations before experimental validation. High-Throughput Screening (HTS) 29.0% USD 1.41 Bn 7.2% HTS provides the experimental validation layer for computational and mechanistic hypotheses by testing compounds across disease-relevant assays, phenotypic models, and dose-response systems before expensive development begins. Technology Platform Genomics-Driven Repurposing 22.0% USD 1.07 Bn 9.0% Genomic and molecular profiling helps identify treatment-eligible patient populations in which an established drug mechanism has stronger biological relevance, supporting more targeted development and trial enrichment. Others 13.0% USD 0.63 Bn 7.0% Real-world evidence, phenotypic screening, literature mining, electronic health records, clinical observations, and mixed data-driven methods complement AI and laboratory screening by validating therapeutic signals across additional evidence sources. End User Pharmaceutical & Biotechnology Companies 62.0% USD 3.01 Bn 9.1% Pharmaceutical and biotechnology companies lead because ownership of marketed or investigational assets provides access to historical safety data, manufacturing information, regulatory files, intellectual property, and commercialization infrastructure. Academic & Research Institutions 22.0% USD 1.07 Bn 7.4% Academic institutions are particularly important for generic medicines, rare diseases, and scientifically credible opportunities with limited immediate commercial incentives, often generating the translational evidence required before industry participation. Contract Research Organizations (CROs) 16.0% USD 0.78 Bn 9.1% CROs support the transition from candidate identification to investable development through assay validation, formulation, pharmacokinetics, clinical trials, biomarker analysis, regulatory documentation, and market-access planning. Geography North America 41.0% USD 1.99 Bn 8.3% North America leads through the combination of FDA activity, NIH and ARPA-H funding, advanced AI and real-world-data platforms, mature pharmaceutical development infrastructure, and established pathways for indication expansion and reimbursement. Europe 27.0% USD 1.31 Bn 7.9% Europe has a structured repurposing ecosystem supported by EMA/HMA scientific advice and national healthcare initiatives, although experience in England also demonstrates the commercial challenges created by weak sponsorship and insufficient evidence for off-patent medicines. Asia Pacific 22.0% USD 1.07 Bn 10.8% Asia Pacific is the fastest-growing regional segment as computational biology, genomics, pharmaceutical manufacturing, translational research, and academic-industry partnerships expand across major healthcare markets. Latin America 6.0% USD 0.29 Bn 9.0% Regional activity remains concentrated in academic translational research, public pharmaceutical programs, infectious-disease research, generic manufacturing, and locally relevant therapeutic-development opportunities. Middle East & Africa 4.0% USD 0.19 Bn 6.2% The market remains comparatively smaller, with opportunities linked to existing-drug availability, infectious and neglected diseases, rare-disease research, public-health programs, technology transfer, and improving translational infrastructure. Drug Repurposing Market Opportunity Map: Why Oncology Leads While Neurology Builds the Next Major Development Pool Oncology accounted for 36.5% of the Drug Repurposing Market, representing USD 1.77 billion in 2025, and is projected to expand at a CAGR of 9.5% during 2026–2032. Oncology has the most mature bridge between published evidence, clinical practice, reimbursement, and formal label expansion. FDA’s Project Renewal evaluates publicly available evidence for long-standing cancer drugs and, by 2024, had facilitated review leading to approval of 15 NDA supplements covering new indications and/or dosage regimens. CMS also recognizes specified compendia when determining medically accepted off-label anticancer uses. The commercial significance is that an older oncology medicine can generate clinically meaningful utilization before or alongside formal label modernization, although off-label use itself should not be treated as equivalent to an FDA-approved repurposed indication. [7,8] Neurology represented 18.5% of the market, equivalent to USD 0.90 billion in 2025, and is projected to grow at a CAGR of 9.2%. High failure rates and long development cycles for novel neurological drugs make known human pharmacology particularly valuable. NIA reports 14 Phase I and II trials testing 11 FDA-approved medicines for Alzheimer’s disease and related dementias; candesartan, nicotine, and metformin generated sufficient early evidence to advance into larger studies, with metformin progressing to Phase II/III evaluation. These programs remain investigational for Alzheimer’s disease, but they demonstrate how public funding can build an evidence package around existing molecules before a conventional commercial sponsor is prepared to invest. [9] Infectious Diseases accounted for 16.0% of the market, representing USD 0.78 billion in 2025, and are projected to expand at a CAGR of 8.9%. Repurposing is most valuable in this segment when an existing product combines known safety and manufacturing with a mechanistic rationale that can be tested quickly against an emerging pathogen or disease complication. WHO’s 2026 therapeutics-prioritization work explicitly includes repurposed candidates for epidemic and pandemic threats. Commercial value is therefore tied not only to clinical efficacy but also to deployability, available supply, formulation, and the ability to move a candidate into appropriately powered efficacy studies before the public-health window changes. [25] Cardiovascular Disorders represented 10.5% of the market, or USD 0.51 billion in 2025, and are projected to record a CAGR of 7.2%. This segment is driven mainly by lifecycle-style indication expansion rather than classic rescue of abandoned generic drugs. Novo Nordisk’s semaglutide franchise illustrates the model: FDA approved an additional Ozempic indication in January 2025 to reduce sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, supported by the 3,533-patient FLOW trial. Semaglutide is a GLP-1 receptor agonist; the commercial relevance is that established mechanism, manufacturing, prescriber familiarity, and sponsor-controlled evidence can support expansion into clinically adjacent populations. [22] Autoimmune and Inflammatory Conditions accounted for 10.5% of the market, representing USD 0.51 billion in 2025, and are projected to expand at a CAGR of 8.5%. Shared immune pathways allow cytokine inhibitors, immunomodulators, and other established therapies to be evaluated across related diseases, but the commercial outcome depends on whether the new indication can support a differentiated label, dosing strategy, patient-selection rationale, or defensible evidence package. Biologics are particularly relevant where a validated immune target operates across multiple conditions, while small molecules retain an advantage when oral administration and low-cost clinical experience support broader testing. Other therapeutic areas accounted for 8.0% of the market, representing USD 0.39 billion in 2025, and are projected to expand at a CAGR of 5.9%. Rare and genetically defined diseases are strategically important within this group because conventional discovery may be difficult to finance for small populations. FDA’s March 2026 expanded approval of Wellcovorin for FOLR1-associated cerebral folate deficiency is a notable proof point: the agency used systematic review of published cases and mechanistic evidence rather than a conventional prospective registration trial. FDA labeling identified 46 reported patients with FOLR1-associated disease in the published literature, showing how a very small evidence base can still become actionable when genotype, mechanism, clinical effect, and regulatory evidence align. [6,23] Drug Repurposing Market Economics: Why Small Molecules Dominate While Off-Patent Assets Face a Sponsorship Gap Small Molecules accounted for 79.0% of the Drug Repurposing Market, representing USD 3.83 billion in 2025, and are projected to expand at a CAGR of 8.2% during 2026–2032. Their leadership reflects decades of accumulated human exposure, established chemistry and manufacturing, oral delivery options, and the ability to create new formulations or routes around a known active ingredient. Anastrozole shows both the clinical potential and economic difficulty of this model. NHS England estimated that around 289,000 women could be eligible for its breast-cancer risk-reduction use; Accord Healthcare undertook licensing work on a not-for-profit basis after an open competitive process. The case demonstrates that a compelling new use can exist even when conventional generic economics provide little incentive for a single manufacturer to fund the regulatory work. [10] Biologics represented 21.0% of the market, equivalent to USD 1.02 billion in 2025, and are projected to grow faster at a CAGR of 10.6%. Their smaller starting share reflects a shorter history of broadly available biologics and more complex manufacturing, but targeted antibodies and other immune-directed products can move across indications when the same biological pathway is relevant in multiple diseases. Biologics also tend to preserve stronger sponsor control over manufacturing, clinical data, and lifecycle strategy than older generic small molecules, improving the economics of formal indication expansion when the new population is commercially meaningful. AI in the Drug Repurposing Market: From Millions of Candidate Matches to Clinically Actionable Assets Computational Modeling & AI-Based Screening accounted for 36.0% of the technology market, representing USD 1.75 billion in 2025, and is projected to expand at a CAGR of 10.3%. AI can integrate drug-target relationships, disease mechanisms, literature, omics, clinical data, and knowledge graphs to rank drug-disease combinations at a scale that manual hypothesis generation cannot match. ARPA-H’s MATRIX program, led by Every Cure, is the clearest current example: the award is worth up to USD 124 million and is designed to score the landscape of approved drugs against human diseases and then advance at least 30 top opportunities into preclinical and clinical validation. Every Cure reported reviewing more than 9,000 repurposing opportunities during 2025 but launched nine active programs, illustrating how large computational funnels narrow sharply before capital-intensive development. [5,14] High-Throughput Screening accounted for 29.0% of the market, representing USD 1.41 billion in 2025, and is projected to grow at a CAGR of 7.2%. Experimental screening remains a critical filter because a computational association does not establish therapeutic effect. Cell-based assays, phenotypic models, dose-response testing, and disease-relevant biological systems help determine whether a ranked candidate produces a reproducible signal and whether the exposure required is clinically plausible. HTS therefore functions less as a competing approach to AI and more as the biological validation layer that prevents attractive algorithms from becoming low-quality development pipelines. Genomics-Driven Repurposing represented 22.0% of the market, or USD 1.07 billion in 2025, and is projected to expand at a CAGR of 9.0%. Genetic and molecular data can convert a broad drug-disease hypothesis into a narrower treatment-eligible population with a stronger mechanistic rationale. The Wellcovorin example is commercially important because the new FDA-approved indication is tied to confirmed FOLR1 variants. This type of biomarker-defined repurposing can reduce biological ambiguity, improve trial enrichment, and create a more defensible treatment proposition than broad empirical off-label use. [6] Other technology approaches accounted for 13.0% of the market, representing USD 0.63 billion in 2025, and are projected to grow at a CAGR of 7.0%. Real-world evidence, literature mining, electronic health records, clinical observations, phenotypic screening, and mixed methods are especially useful for confirming whether an AI or mechanistic signal appears in real patients. Atropos Health’s collaboration with Every Cure uses GENEVA OS and the Atropos Evidence Network to test repurposing signals against real-world clinical data and emulate treatment effects, creating an evidence bridge between computational ranking and prospective development. [20] Drug Repurposing Market Commercialization Structure: Why Pharma Leads but Academia and CROs Fill the Incentive Gaps Pharmaceutical and Biotechnology Companies accounted for 62.0% of the Drug Repurposing Market, representing USD 3.01 billion in 2025, and are projected to expand at a CAGR of 9.1% during 2026–2032. Existing product owners control manufacturing information, safety databases, regulatory history, proprietary clinical data, and commercial infrastructure. The 1985–2024 longitudinal analysis found that large companies accounted for most repurposed approvals and that repurposing occurred more rapidly when development rights stayed with the original owner. That evidence supports a straightforward commercial conclusion: access to the original data package and control of the asset can be as important as scientific novelty. [2] Academic and Research Institutions represented 22.0% of the market, equivalent to USD 1.07 billion in 2025, and are projected to grow at a CAGR of 7.4%. Universities, hospitals, public agencies, and nonprofits are disproportionately important where a generic drug has strong scientific rationale but little conventional return on investment. NIA’s Alzheimer’s repurposing portfolio and the EMA/HMA pilot show how public and academic infrastructure can generate mechanistic and clinical evidence before a commercial sponsor exists. The limitation is that publication alone rarely solves ownership, manufacturing, regulatory, and reimbursement requirements. [9,12] Contract Research Organizations accounted for 16.0% of the market, representing USD 0.78 billion in 2025, and are projected to expand at a CAGR of 9.1%. Repurposed assets still require assay validation, formulation, toxicology where needed, pharmacokinetic work, clinical protocol design, trial execution, biomarkers, regulatory writing, and market-access planning. NIDA’s SUD repurposing-center NOFO explicitly incorporated intellectual-property, freedom-to-operate, target-product-profile, regulatory, and market-access capabilities, demonstrating that the commercially relevant service layer begins after candidate identification rather than ending there. Nuformix similarly relies on an external development and partnering model around its repurposed assets. [16,18] Drug Repurposing Market Regional Investment Landscape: Where Evidence and Commercialization Infrastructure Are Most Mature North America accounted for 41.0% of the Drug Repurposing Market, representing USD 1.99 billion in 2025, and is projected to expand at a CAGR of 8.3% during 2026–2032. The region combines FDA indication-expansion pathways, NIH-funded translational research, ARPA-H’s MATRIX investment, mature pharmaceutical development, real-world-data platforms, and established reimbursement mechanisms. Every Cure and Atropos Health illustrate the emerging AI-to-RWE evidence stack, while FDA’s 2026 RFI and workshop show direct federal attention to the sponsor-incentive problem. The region’s advantage is not simply research volume; it is the availability of multiple organizations capable of carrying an asset from hypothesis through validation, regulatory interaction, and commercialization. [3,4,5,20] Europe represented 27.0% of the market, equivalent to USD 1.31 billion in 2025, and is projected to grow at a CAGR of 7.9%. The EMA/HMA repurposing pilot ran from October 2021 through December 2024 and provided tailored scientific advice, including fee waivers for eligible academic sponsors. England’s anastrozole program then demonstrated a national pathway for moving an off-patent medicine into a licensed preventive indication. At the same time, the April 2025 suspension of NHS England’s broader program provides an important counterweight: regulators and health systems can facilitate evidence and licensing, but they cannot create a viable program when the evidence base or sponsor economics are insufficient. [10,11,12] Asia Pacific accounted for 22.0% of the market, representing USD 1.07 billion in 2025, and is projected to record the fastest regional CAGR of 10.8%. The region’s growth profile is supported by expanding computational biology, genomics, translational research, pharmaceutical manufacturing, and academic-industry collaboration. Unlike North America and Europe, however, no single region-wide repurposing framework dominates. Commercial development is likely to remain heterogeneous, with opportunities emerging through national research programs, generic-drug expertise, contract development, and partnerships that connect locally generated evidence with global regulatory and licensing capabilities. Latin America represented 6.0% of the market, equivalent to USD 0.29 billion in 2025, and is projected to expand at a CAGR of 9.0%. Repurposing activity is less institutionalized than in North America or Europe, and reliable region-wide data on formal new-indication development remain limited. The most credible opportunity base lies in academic translational research, public pharmaceutical institutions, infectious-disease programs, generics, and local manufacturing. For investors, the relevant distinction is between scientific repurposing activity and a commercial pathway that includes sponsor ownership, regulatory submission, supply, and reimbursement. Middle East & Africa accounted for 4.0% of the market, representing USD 0.19 billion in 2025, and are projected to expand at a CAGR of 6.2%. The regional market remains smaller and is shaped by existing-drug availability, infectious and neglected diseases, rare-disease research, and variable regulatory and specialist infrastructure. Repurposing can be strategically attractive where a known medicine and existing supply chain lower development barriers, but commercialization frequently depends on public-health procurement, nonprofit funding, technology transfer, or multinational partnerships rather than a conventional high-margin pharmaceutical model. Drug Repurposing Market Competitive Ecosystem: How Pharma, Repurposing Specialists, Nonprofits and Evidence Platforms Capture Value The Drug Repurposing Market is better understood as a competitive ecosystem than as a conventional list of drug manufacturers. Originator pharmaceutical companies compete through indication expansion and proprietary data; specialist biotechs create value through formulation, new-use IP, orphan positioning, and licensing; nonprofits and public programs de-risk scientifically compelling but commercially neglected opportunities; and data or RWE platforms help determine which signals deserve clinical investment. Competitive advantage therefore depends on control of the asset, evidence, development rights, regulatory execution, and the ability to capture value after a new use is validated. Every Cure – Systematic Discovery and Nonprofit Development Every Cure is a nonprofit organization built specifically around systematic drug repurposing. Its MATRIX platform combines biomedical knowledge with AI-based ranking, while its operating model extends into preclinical validation, clinical research, guideline or label work, and patient access. The organization reviewed more than 9,000 opportunities and launched nine active programs in 2025; by July 2026, it reported 12 active repurposing programs. ARPA-H’s award of up to USD 124 million gives Every Cure a differentiated role in advancing programs that may be scientifically strong but too commercially fragmented for conventional early investment. For example, its platform can identify an established medicine with a potential use in a rare or neglected disease, rank the opportunity using biological and clinical evidence, and then support validation and access planning. [14,15,5] Nuformix plc – Formulation IP and Licensing-Led Repurposing Nuformix is a specialist repurposing company focused on generating differentiated pharmaceutical forms and licensing opportunities in fibrosis and oncology. Its lead NXP002 program uses tranilast in a proprietary form intended for inhaled delivery in idiopathic pulmonary fibrosis and remains preclinical; tranilast has prior oral use in allergy, while the repurposed concept targets pulmonary fibrosis through pathways including TGF-beta/SMAD signaling. FDA granted Orphan Drug Designation to tranilast lysinate for IPF in March 2026, but this designation is not FDA approval. For example, Nuformix can create value by converting an established oral medicine into a potentially more suitable inhaled formulation, securing new-use or formulation-related IP, and presenting the program to a larger pharmaceutical partner. Its business model is centered on building evidence, IP, and partner interest before out-licensing or collaborating on later development. [17,18] Oxilio – Asset Acquisition and Downstream Oncology Development Oxilio illustrates the asset-transfer model. It acquired ownership of Nuformix’s NXP001 patent portfolio covering proprietary forms of aprepitant, an established NK1-receptor antagonist used in oncology supportive care, and is responsible for further development around potential oncology indications. For example, Oxilio can take a repurposed asset with an existing safety and clinical-use history, develop a differentiated formulation or indication strategy, and advance it toward oncology applications that may require additional preclinical or clinical evidence. The commercial relevance is less about current product revenue and more about how a repurposing specialist can create differentiated IP around an existing molecule and then transfer the program to a developer willing to finance later-stage work. Nuformix retained milestone and royalty rights under the transaction. [19] Accord Healthcare – Generic Sponsorship and Formal Label Expansion Accord Healthcare represents a different model: a generic manufacturer acting as the regulatory sponsor for a clinically established new use. NHS England selected Accord through an open competitive process to undertake the anastrozole licensing work on a not-for-profit basis for breast-cancer risk reduction in postmenopausal women at increased risk. For example, Accord can use its regulatory, manufacturing, and pharmacovigilance capabilities to convert evidence for an established generic medicine into a formal licensed indication, even when the medicine itself has limited commercial exclusivity. The example is important because it shows a practical mechanism for solving the “who pays for the licence?” problem when an inexpensive generic has meaningful evidence but weak proprietary economics. [10] Atropos Health – Real-World Evidence as a Validation Layer Atropos Health does not own a repurposed drug portfolio; it competes in the evidence layer. Its GENEVA OS and Atropos Evidence Network are used with Every Cure to test AI-generated repurposing signals against real-world clinical data and emulate potential treatment effects in real patient populations. For example, the platform can compare outcomes among patients who received an established medicine for a proposed new indication with outcomes among clinically similar patients who did not receive it, helping researchers assess treatment effects, identify responsive subgroups, and design prospective trials. This capability is strategically relevant because AI discovery creates a large number of hypotheses, while real-world evidence can help prioritize which candidates, subpopulations, and study designs merit prospective investment. [20] Drug Repurposing Market Outlook to 2032: Investable Programs Move Beyond Scientific Signals The strongest opportunities through 2032 are likely to be programs in which repurposing creates a financeable new asset rather than merely an interesting new use. That includes protected indication expansions, orphan opportunities, biomarker-defined populations, new formulations or routes that enable the therapeutic use, evidence packages capable of supporting formal label action, and AI-selected candidates backed by experimental or clinical validation. The 451-approval historical record shows that repurposing is durable, but it also shows that development is faster when the original owner retains control of the asset and its data. [2] AI will expand the candidate universe much faster than it expands the investable pipeline. Every Cure’s 2025 funnel - more than 9,000 opportunities reviewed but nine active programs launched - demonstrates the scale of filtering required before a drug-disease relationship becomes a development program. High-throughput screening, genomics, real-world evidence, formulation work, clinical trials, and sponsor economics remain the decisive gates. Companies that can integrate these layers are better positioned than platforms that stop at computational prediction. [14] The most persistent constraint will remain off-patent commercialization. NHS England’s suspended program and the EMA/HMA pilot both show that regulatory support cannot substitute for a sufficiently strong evidence base or a sponsor willing to own the submission, supply the product, and absorb development costs. For generic medicines, public funding, nonprofit developers, competitive licensing, orphan incentives, formulation IP, and alternative reimbursement models may therefore be as important as the underlying pharmacology. [11,12,13] SMR expects the Drug Repurposing Market to shift from opportunistic repositioning toward portfolio-based candidate selection and evidence engineering. The programs most likely to create durable revenue will combine four elements: a clinically credible new use, a defined treatment-eligible population, a defensible evidence or exclusivity strategy, and a clear path from approval or accepted use to reimbursement and supply. Scientific signals that lack ownership, development capital, or market access will continue to generate publications without necessarily creating commercial products. Drug Repurposing Market Report Coverage Table Report Attribute Details Forecast Period 2026–2032 Market Size Value in 2025 USD 4.85 Billion Revenue Forecast in 2032 USD 8.72 Billion Overall Growth Rate 8.7% CAGR Base Year for Estimation 2025 Historical Data 2019–2024 Unit USD Billion Segmentation Therapeutic Area, Drug Type, Technology Platform, End User, and Geography By Therapeutic Area Oncology, Neurology, Infectious Diseases, Cardiovascular Disorders, Autoimmune & Inflammatory Conditions, and Others By Drug Type Small Molecules and Biologics By Technology Platform Computational Modeling & AI-Based Screening, High-Throughput Screening (HTS), Genomics-Driven Repurposing, and Others By End User Pharmaceutical & Biotechnology Companies, Academic & Research Institutions, and Contract Research Organizations (CROs) By Region North America, Europe, Asia Pacific, Latin America, and Middle East & Africa Country Scope United States, Canada, Mexico, Germany, United Kingdom, France, Italy, Spain, China, Japan, India, South Korea, Australia, Brazil, Saudi Arabia, United Arab Emirates, and South Africa Market Drivers Faster development timelines, lower clinical risk, accumulated safety evidence, indication expansion, AI-based candidate screening, high-throughput validation, genomics, real-world evidence, orphan-drug development, and demand for therapies addressing unmet medical needs Customization Option Available upon request. Frequently Asked Question About This Report Q1. How is technology advancement influencing adoption in the market? A1. AI, machine learning, knowledge graphs, genomics, and real-world evidence are helping developers screen thousands of drug-disease combinations before committing to expensive clinical programs. These tools improve candidate prioritization but still require experimental and clinical validation before a repurposing hypothesis becomes an investable asset. Q2. Which industries are using this technology the most in the market? A2. Pharmaceutical and biotechnology companies are the largest users because they can reuse existing safety data, manufacturing knowledge, regulatory files, and commercial infrastructure. Academic institutions and CROs also play important roles in validating generic-drug opportunities and moving promising candidates into development. Q3. What regulatory changes are affecting the industry? A3. Regulators are creating more structured pathways for evaluating new uses of established medicines, particularly in oncology, rare diseases, and off-patent products. FDA initiatives, EMA/HMA scientific-advice programs, and formal label-expansion pathways can reduce uncertainty, although a willing sponsor and adequate evidence are still required. Q4. How is competition evolving among key players in the market? A4. Competition increasingly extends beyond pharmaceutical companies to specialist repurposing firms, nonprofit developers, AI platforms, and real-world-evidence providers. Companies differentiate through asset ownership, new-use intellectual property, formulation strategies, biomarker selection, evidence generation, and regulatory execution. Q5. What factors should businesses consider before entering this industry? A5. Businesses need to assess intellectual-property protection, freedom to operate, existing clinical evidence, development rights, regulatory strategy, and reimbursement potential. A scientifically attractive new use may have limited commercial value if the medicine is generic and no organization has an economic incentive to fund development. Q6. How is demand changing across different regions in the market? A6. North America remains the largest market because of strong pharmaceutical infrastructure, federal research funding, AI platforms, and established regulatory pathways. Asia Pacific is expanding faster as computational biology, genomics, manufacturing, and academic-industry collaboration develop across major healthcare markets. Q7. How will the industry evolve over the next few years? A7. The industry is likely to move from opportunistic drug repositioning toward systematic portfolio-based candidate selection and evidence engineering. The strongest programs will combine a credible new indication with a defined patient population, defensible commercial rights, and a clear path to approval, reimbursement, and supply. Sources: [1] U.S. FDA - Drug Repurposing - https://www.fda.gov/drugs/resources-drugs/drug-repurposing [2] Communications Medicine - Impact of drug repurposing between 1985 and 2024 on pharmaceutical innovation - https://www.nature.com/articles/s43856-025-01344-1 [3] U.S. FDA - FDA Advances Drug Repurposing to Address Unmet Medical Needs (May 11, 2026) - https://www.fda.gov/news-events/press-announcements/fda-advances-drug-repurposing-address-unmet-medical-needs [4] U.S. FDA - Drug Repurposing: Considerations for Selection Criteria and Prioritization (Aug. 5, 2026) - https://www.fda.gov/drugs/news-events-human-drugs/drug-repurposing-considerations-selection-criteria-and-prioritization-08052026 [5] ARPA-H - MATRIX: ML/AI-Aided Therapeutic Repurposing In eXtended uses - https://arpa-h.gov/explore-funding/awards/1141 [6] U.S. FDA - First Treatment for Cerebral Folate Transport Deficiency / Wellcovorin (March 10, 2026) - https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-cerebral-folate-transport-deficiency [7] U.S. FDA Oncology Center of Excellence - Project Renewal, 2024 Regulatory Programs - https://www.fda.gov/about-fda/2024-oce-annual-report/oce-regulatory-programs-2024 [8] CMS - Compendia 1861(t)(2): Anti-cancer - https://www.cms.gov/medicare/coverage/determination-process/basics/compendia-1861-t2-anti-cancer [9] National Institute on Aging - Drug Repurposing: Early Clinical Development - https://www.nia.nih.gov/research/milestones/translational-clinical-research/pharmacological/milestone-7-d [10] NHS England - Anastrozole repurposing announcement - https://www.england.nhs.uk/2023/11/tens-of-thousands-of-women-set-to-benefit-from-repurposed-nhs-drug-to-prevent-breast-cancer/ [11] NHS England - Repurposing medicines in the NHS in England; program suspended April 2025 - https://www.england.nhs.uk/medicines-2/medicines-repurposing-programme/ [12] European Medicines Agency / HMA - EU Repurposing Pilot and Scientific Advice - https://www.ema.europa.eu/en/human-regulatory-overview/research-development/scientific-advice-protocol-assistance/parallel-scientific-advice-special-development-aspects-or-product-types [13] U.S. FDA - New Clinical Investigation Exclusivity (3-Year Exclusivity) Draft Guidance, March 2026 - https://www.fda.gov/regulatory-information/search-fda-guidance-documents/new-clinical-investigation-exclusivity-3-year-exclusivity-drug-products-questions-and-answers [14] Every Cure - 2025 Annual Report - https://everycure.org/2025-annual-report/ [15] Every Cure - July 2026 Portfolio Update - https://everycure.org/july-2026/ [16] NIH/NIDA - RFA-DA-26-020 Drug Repurposing and Repositioning Center for Substance Use Disorders - https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-26-020.html [17] Nuformix - NXP002 (inhaled tranilast) for IPF - preclinical - https://nuformix.com/pipeline/nxp002-fibrosis/ [18] Nuformix - Half Year Report, six months ended March 31, 2026 - https://www.investegate.co.uk/announcement/rns/nuformix--nfx/half-year-report/9588621 [19] Nuformix - Annual Report and Accounts for year ended Sept. 30, 2025 - https://nuformix.com/documents/annual-report-and-accounts-for-the-year-ended-30-september-2025/ [20] Atropos Health - Partnership with Every Cure for real-world evidence confirmation of repurposing opportunities - https://www.atroposhealth.com/partnership-announcement-atropos-health-and-every-cure-2024/ [21] CMS Medicare Coverage Database - A59217 Off-Label Use of Chemotherapeutic Drugs and Biologicals for Non-Cancer Indications - https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=59217 [22] U.S. FDA - Ozempic supplemental approval, January 2025 - https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/209637Orig1s025ltr.pdf [23] U.S. FDA - Wellcovorin 2026 Prescribing Information / clinical evidence summary - https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/018342s015lbl.pdf [24] PubMed - Drug Repurposing as an Effective Drug Discovery Strategy: A Critical Review (2025) - https://pubmed.ncbi.nlm.nih.gov/41497349/ [25] World Health Organization - Technical Advisory Group on Therapeutics Prioritization (TAG-TP) - https://www.who.int/groups/technical-advisory-group-on-therapeutics-prioritization Table of Contents - Global Drug Repurposing Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Therapeutic Area, Drug Type, Technology Platform, End User, and Geography Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Therapeutic Area, Drug Type, Technology Platform, End User, and Geography Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Therapeutic Area, Drug Type, Technology Platform, and End User Investment Opportunities in the Drug Repurposing Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in Oncology Repurposing, Neurology Programs, Infectious Disease Applications, Cardiovascular Lifecycle Expansion, Autoimmune & Inflammatory Conditions, AI-Based Candidate Screening, Genomics-Driven Repurposing, Real-World Evidence, and Biomarker-Defined Development Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Strategic Importance of Drug Repurposing in Faster Development, Unmet Medical Needs, Lifecycle Expansion, Rare Diseases, and Evidence-Based New Therapeutic Uses Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Regulatory, Intellectual Property, Sponsorship, Evidence, and Market-Access Factors Role of AI-Based Screening, High-Throughput Screening, Genomics, Real-World Evidence, and Computational Modeling in Market Expansion Clinical Validation, Biomarker Selection, Formulation Development, Licensing, Label Expansion, and Reimbursement Trends in Drug Repurposing Global Drug Repurposing Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Therapeutic Area: Oncology Neurology Infectious Diseases Cardiovascular Disorders Autoimmune & Inflammatory Conditions Others Market Analysis by Drug Type: Small Molecules Biologics Market Analysis by Technology Platform: Computational Modeling & AI-Based Screening High-Throughput Screening (HTS) Genomics-Driven Repurposing Others Market Analysis by End User: Pharmaceutical & Biotechnology Companies Academic & Research Institutions Contract Research Organizations (CROs) Market Analysis by Geography: North America Europe Asia Pacific Latin America Middle East & Africa Regional Market Analysis North America Drug Repurposing Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Therapeutic Area, Drug Type, Technology Platform, and End User Country-Level Breakdown: United States Canada Mexico Europe Drug Repurposing Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Therapeutic Area, Drug Type, Technology Platform, and End User Country-Level Breakdown: Germany United Kingdom France Italy Spain Rest of Europe Asia Pacific Drug Repurposing Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Therapeutic Area, Drug Type, Technology Platform, and End User Country-Level Breakdown: China India Japan South Korea Australia Rest of Asia-Pacific Latin America Drug Repurposing Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Therapeutic Area, Drug Type, Technology Platform, and End User Country-Level Breakdown: Brazil Argentina Rest of Latin America Middle East & Africa Drug Repurposing Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Therapeutic Area, Drug Type, Technology Platform, and End User Country-Level Breakdown: GCC Countries South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: Every Cure Nuformix plc Oxilio Accord Healthcare Atropos Health Novo Nordisk Pfizer Inc. Johnson & Johnson AstraZeneca Competitive Landscape and Strategic Insights Benchmarking Based on Drug Ownership, Clinical Evidence, Intellectual Property, Regulatory Strategy, Data Assets, Technology Capabilities, Development Infrastructure, and Regional Presence Asset Qualification, Evidence Generation, and Sponsorship Capability Analysis AI-Based Candidate Discovery and Computational Repurposing Positioning Oncology, Neurology, Infectious Disease, Cardiovascular, and Autoimmune & Inflammatory Repurposing Competitiveness Real-World Evidence, Genomics, Biomarker Development, and Clinical Validation Strategy Analysis Appendix Abbreviations and Terminologies Used in the Report References and Sources List of Tables Market Size by Therapeutic Area, Drug Type, Technology Platform, End User, and Geography (2026–2032) Regional Market Breakdown by Segment Type (2026–2032) Competitive Benchmarking of Leading Vendors Regulatory, Intellectual Property, Sponsorship, and Commercialization Risk Analysis Technology Adoption Trends Across Computational Modeling & AI-Based Screening, High-Throughput Screening, Genomics-Driven Repurposing, and Real-World Evidence List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Therapeutic Area, Drug Type, Technology Platform, and End User (2025 vs. 2032) Global Drug Repurposing Ecosystem and Value Chain Analysis